Plain-language overview
There is no single universally accepted way to describe an extracellular-vesicle dose. Different studies may report particle number, total protein, the number of producer cells, the amount of a selected cargo molecule, or a functional biological activity.
These measurements are not interchangeable. Two EV products with the same particle count can differ greatly in purity, cargo, biological activity, source cells, and manufacturing process.
A meaningful dose therefore needs to identify exactly what was measured and show how that measurement relates to biological activity, exposure, safety, and the intended clinical use.
Particle number
Particle number is a common way to report how many detectable particles are present in an EV preparation.
Methods such as nanoparticle tracking analysis or resistive-pulse sensing can estimate this number, but results depend on instrument settings, detection limits, dilution, aggregation, and the presence of non-EV particles.
A nominal dose of a certain number of particles therefore does not mean that every counted particle is an EV or that every EV has the same biological activity.
Figure 1 placeholder — Particle number
Protein quantity
Protein quantity reports the amount of total protein in the EV preparation, usually in micrograms or milligrams.
The measured total protein can include proteins from EV membranes and cargo as well as soluble proteins, protein aggregates, lipoproteins, or other contaminants.
For that reason, equal protein quantities from two EV preparations do not necessarily represent equal numbers of EVs or equal biological potency.
Figure 2 placeholder — Protein quantity
Cell-equivalent dose
Cell-equivalent dose relates the EV preparation to the number of producer cells, the amount of conditioned medium, culture area, or another measure of cellular production.
EV output changes with cell source, donor, passage, confluence, culture duration, oxygen level, stimulation, and cell health. The manufacturing yield also depends on how efficiently EVs are recovered during processing.
A source-cell equivalent can therefore help describe manufacturing, but it does not directly tell how many active EVs are administered.
Figure 3 placeholder — Cell-equivalent dose
Cargo-based dosing
Cargo-based dosing defines dose according to the amount of a selected EV-associated molecule, such as a protein, lipid, messenger RNA, microRNA, or engineered therapeutic cargo.
This can be useful when the selected cargo is known to be important to the intended mechanism. However, cargo localization matters: measuring a molecule in the bulk preparation does not prove that it is inside EVs.
Delivery efficiency and target engagement also matter. The cargo must reach the appropriate cells and biological target in a sufficient amount before a cargo-based measurement can represent a meaningful biological dose.
Figure 4 placeholder — Cargo-based dosing
Functional assays
Functional assays measure what an EV preparation does in a biological test rather than simply measuring how much material is present.
A potency assay might measure an effect on inflammatory signaling, endothelial cells, cell survival, receptor activation, gene expression, or another mechanism relevant to the intended product.
Potency and quantity are different. A large amount of weakly active material is not necessarily equivalent to a smaller amount of a more active preparation.
Figure 5 placeholder — Functional assays
Dose-response testing
Dose-response testing examines whether changing the amount of EV product changes the biological response.
A dose-response relationship can help identify a minimally active dose, a plateau where additional product adds little effect, or saturation of a biological pathway. Some complex biological responses may also be non-linear.
Exposure time, biodistribution, clearance, route of administration, and repeat dosing can all change the response. Dose-response information should therefore be generated for the actual product and intended use.
Figure 6 placeholder — Dose-response testing
Lack of universal dosing standards
Lack of universal dosing standards means that there is no accepted conversion that makes particle number, protein mass, producer-cell equivalents, cargo amount, or potency interchangeable across EV products.
Differences in source cells, manufacturing, separation, purity, composition, measurement methods, route, indication, and patient biology prevent simple dose comparisons.
A dose used in one study cannot automatically be transferred to another EV preparation simply because both products are described as extracellular vesicles or exosomes.
Figure 7 placeholder — Lack of universal dosing standards
Nominal dose versus biological dose
A nominal dose is the amount stated on paper or administered according to a selected measurement. A biological dose reflects the exposure or activity that actually matters to the biological system.
Connecting these two concepts requires product characterization, potency testing, and information about where the product goes and how long it remains available.
Normalization and comparison
Normalization describes how researchers adjust dose for comparison, such as particles per cell, protein per cell, particles per kilogram, or another denominator.
Different normalization methods can make the same experimental exposure appear different. The method should therefore be stated clearly whenever studies or products are compared.
Route and repeat dosing
The same nominal EV dose can produce different tissue exposure when given intravenously, locally, into a joint, by inhalation, topically, or through another route.
Repeat dosing adds further variables, including the interval between doses, clearance, accumulation, changing tissue conditions, and cumulative dose. Total cumulative amount alone does not fully describe the timing of exposure.
Dose-ranging studies
A dose-ranging study evaluates more than one dose level to understand the relationship between amount, biological or clinical response, and safety.
For therapeutic development, these studies are important because a dose selected from laboratory or animal experiments may not be the most appropriate dose in humans.
Questions patients should ask
How is the EV dose measured: particle number, protein quantity, source-cell equivalent, cargo amount, or functional potency? What laboratory method measures that dose? How pure is the preparation? Is there a validated potency assay? Has this exact product undergone dose-response or human dose-ranging studies? What route was studied? Is the proposed dose based on this product or borrowed from a different EV preparation?
Bottom line
There is no universal EV dose unit. Particle count, protein mass, producer-cell equivalents, cargo amount, and functional activity describe different aspects of a product.
Strong dosing evidence defines what is measured, shows how that measurement relates to potency and biological exposure, evaluates dose-response and safety for the actual product, and does not assume that nominal doses can be transferred across different EV preparations.
How this review was prepared
This Patient Edition was derived directly from the explicitly approved 0610 Professional Edition and preserves the same seven controlling Points.